These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 21615159

  • 1. A new protocol for predicting novel GSK-3β ATP competitive inhibitors.
    Fang J, Huang D, Zhao W, Ge H, Luo HB, Xu J.
    J Chem Inf Model; 2011 Jun 27; 51(6):1431-8. PubMed ID: 21615159
    [Abstract] [Full Text] [Related]

  • 2. Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3β inhibitors through virtual screening.
    Zhang P, Hu HR, Huang ZH, Lei JY, Chu Y, Ye DY.
    Bioorg Med Chem Lett; 2012 Dec 01; 22(23):7232-6. PubMed ID: 23099099
    [Abstract] [Full Text] [Related]

  • 3. Identification and in vitro evaluation of new leads as selective and competitive glycogen synthase kinase-3β inhibitors through ligand and structure based drug design.
    Darshit BS, Balaji B, Rani P, Ramanathan M.
    J Mol Graph Model; 2014 Sep 01; 53():31-47. PubMed ID: 25064440
    [Abstract] [Full Text] [Related]

  • 4. 3D-QSAR and molecular docking studies on pyrazolopyrimidine derivatives as glycogen synthase kinase-3beta inhibitors.
    Dessalew N, Patel DS, Bharatam PV.
    J Mol Graph Model; 2007 Mar 01; 25(6):885-95. PubMed ID: 17018257
    [Abstract] [Full Text] [Related]

  • 5. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
    Arfeen M, Patel R, Khan T, Bharatam PV.
    J Biomol Struct Dyn; 2015 Mar 01; 33(12):2578-93. PubMed ID: 26209183
    [Abstract] [Full Text] [Related]

  • 6. Use of molecular modeling, docking, and 3D-QSAR studies for the determination of the binding mode of benzofuran-3-yl-(indol-3-yl)maleimides as GSK-3beta inhibitors.
    Kim KH, Gaisina I, Gallier F, Holzle D, Blond SY, Mesecar A, Kozikowski AP.
    J Mol Model; 2009 Dec 01; 15(12):1463-79. PubMed ID: 19440740
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Structure based de novo design of novel glycogen synthase kinase 3 inhibitors.
    Dessalew N, Bharatam PV.
    Bioorg Med Chem; 2007 Jun 01; 15(11):3728-36. PubMed ID: 17399989
    [Abstract] [Full Text] [Related]

  • 10. 3D-QSAR and docking studies of selective GSK-3beta inhibitors. Comparison with a thieno[2,3-b]pyrrolizinone derivative, a new potential lead for GSK-3beta ligands.
    Lescot E, Bureau R, Sopkova-de Oliveira Santos J, Rochais C, Lisowski V, Lancelot JC, Rault S.
    J Chem Inf Model; 2005 Jun 01; 45(3):708-15. PubMed ID: 15921460
    [Abstract] [Full Text] [Related]

  • 11. Andrographolide activates the canonical Wnt signalling pathway by a mechanism that implicates the non-ATP competitive inhibition of GSK-3β: autoregulation of GSK-3β in vivo.
    Tapia-Rojas C, Schüller A, Lindsay CB, Ureta RC, Mejías-Reyes C, Hancke J, Melo F, Inestrosa NC.
    Biochem J; 2015 Mar 01; 466(2):415-30. PubMed ID: 25423492
    [Abstract] [Full Text] [Related]

  • 12. Design, synthesis and biological evaluation of benzothiazepinones (BTZs) as novel non-ATP competitive inhibitors of glycogen synthase kinase-3β (GSK-3β).
    Zhang P, Hu HR, Bian SH, Huang ZH, Chu Y, Ye DY.
    Eur J Med Chem; 2013 Mar 01; 61():95-103. PubMed ID: 23047001
    [Abstract] [Full Text] [Related]

  • 13. Structural characterization of the GSK-3beta active site using selective and non-selective ATP-mimetic inhibitors.
    Bertrand JA, Thieffine S, Vulpetti A, Cristiani C, Valsasina B, Knapp S, Kalisz HM, Flocco M.
    J Mol Biol; 2003 Oct 17; 333(2):393-407. PubMed ID: 14529625
    [Abstract] [Full Text] [Related]

  • 14. Novel benzothiazinones (BTOs) as allosteric modulator or substrate competitive inhibitor of glycogen synthase kinase 3β (GSK-3β) with cellular activity of promoting glucose uptake.
    Zhang P, Li S, Gao Y, Lu W, Huang K, Ye D, Li X, Chu Y.
    Bioorg Med Chem Lett; 2014 Dec 15; 24(24):5639-5643. PubMed ID: 25467150
    [Abstract] [Full Text] [Related]

  • 15. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
    Dou X, Jiang L, Wang Y, Jin H, Liu Z, Zhang L.
    Bioorg Med Chem Lett; 2018 Jan 15; 28(2):160-166. PubMed ID: 29208522
    [Abstract] [Full Text] [Related]

  • 16. Olanzapine inhibits glycogen synthase kinase-3beta: an investigation by docking simulation and experimental validation.
    Mohammad MK, Al-Masri IM, Taha MO, Al-Ghussein MA, Alkhatib HS, Najjar S, Bustanji Y.
    Eur J Pharmacol; 2008 Apr 14; 584(1):185-91. PubMed ID: 18295757
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. From a natural product lead to the identification of potent and selective benzofuran-3-yl-(indol-3-yl)maleimides as glycogen synthase kinase 3beta inhibitors that suppress proliferation and survival of pancreatic cancer cells.
    Gaisina IN, Gallier F, Ougolkov AV, Kim KH, Kurome T, Guo S, Holzle D, Luchini DN, Blond SY, Billadeau DD, Kozikowski AP.
    J Med Chem; 2009 Apr 09; 52(7):1853-63. PubMed ID: 19338355
    [Abstract] [Full Text] [Related]

  • 20. Discovery of novel GSK-3β inhibitors with potent in vitro and in vivo activities and excellent brain permeability using combined ligand- and structure-based virtual screening.
    Khanfar MA, Hill RA, Kaddoumi A, El Sayed KA.
    J Med Chem; 2010 Dec 23; 53(24):8534-45. PubMed ID: 21082766
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.